Statement of Need
For the better part of the last 30 years, minimal advances were made in the management and treatment of the three primary myeloproliferative disorders (MPDs)— polycythemia vera, primary myelofibrosis, and essential thrombocythemia. However, with the 2005 identification of the role of JAK2 mutations in the development of MPDs, a new wave of research began, and a number of novel agents have emerged in clinical trials. The diagnosis, management, and treatment of patients with MPDs has begun to once again evolve and grow more complicated. While this serves as potentially great news for MPD patients, it serves as a significant challenge for hematologists/oncologists (hem/oncs) whose education surrounding MPDs ended in medical school. The primary educational needs of community-based hematologists and oncologists regarding MPDs include information about new diagnostic and treatment guidelines, emerging data from clinical trials, and a general overview of the MPDs and how they should be treated.

Learning Objectives
At the conclusion of this initiative, learners should be able to accomplish the following:

• Identify differentiating characteristics of the three primary MPDs based upon diagnostic guidelines recently published by the World Health Organization
• Differentiate the mechanisms of action of JAK2 inhibitors, as well as other novel agents, in late-stage clinical trials for the treatment of patients with MPDs
• Recognize common obstacles faced by hem/oncs in the current management and treatment of MPDs and employ processes to overcome these obstacles in clinical practice

Target Audience
This educational initiative has been developed to meet the educational needs of U.S.-based hematologists and oncologists, particularly those in community-based practices who frequently see and refer patients with MPDs.

Educational Planning Committee

Ruben A. Mesa, MD (Chair) Professor of Medicine Consultant of Hematology & Oncology Mayo Clinic Scottsdale, AZ	Srdan Verstovsek, MD, PhD Associate Professor, Department of Leukemia Division of Cancer Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX
Ross L. Levine, MD Assistant Member Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York, NY	Robert Rosen Chairman MPD Foundation Chicago, IL

Educational Planning Committee Disclosures
It is the policy of the Institute for Continuing Healthcare Education (the Institute) that the education presented at Institute-provided, CME-certified activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, the Institute provides information that faculty have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Any relationships faculty members may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.

Relationships are abbreviated as follows: A, Advisor/review panel member; C, Consultant; G, Grant/research support recipient; E, Education committee; H, Honoraria; PE, Promotional event talks;
S, Stock shareholder; SB, Speakers’ Bureau; O, Other.

Ross L. Levine, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Novartis/A; Cephalon Inc., Incyte Corporation/H.

Ruben A. Mesa, MD, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of this activity.

Robert Rosen has disclosed the following relevant financial relationships that have occurred within the past 12 months: Sandoz, Millennium Pharmaceuticals/A; Genetech, Biogen-Idec, Cephalon Corporation, Eli Lilly and Company/C, SB

Srdan Verstovsek, MD, PhD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: S*BIO Pte Ltd./A,G; Incyte Corporation/G,H; Novartis/G,P; ZioPharm Oncology, Inc./C; Eisai, Inc./P; Hoffman La-Roche Ltd., Schering-Plough Corporation, Celgene Corporation, GlaxoSmithKline, Exelixis, Inc., Cephalon, Inc., Millenium Pharmaceuticals, Inc., Gemin X Pharmaceuticals/G.

Off-label and/or investigational use of the following products will be discussed within the content of this live activity: INCB1842, XL019, TG101348, AZD1480, SB1518, CEP-701, pegylated interferon-alfa-2a, pomalidomide, and AUY922, all for the treatment of myeloproliferative disorders.

Activity Development, Management, and Content Validation Team Disclosures
Cathy Pagano, Rob Naticchia, BS, CMR, CCMEP, John Ruggiero, MPA, PhD, Barbara L. Morgan, MLA, CPM, Scott Kober, BS, CCMEP, Karen J. Thomas, BSBA, CCMEP, Sandra Davidson, BA, Tina Chiu, MEd, Melissa M. Schepacarter, BA, CMP, and Courtney Cohen, BFA are employees of the Institute for Continuing Healthcare Education, and are collectively responsible for the planning, development, management, and evaluation of this CME activity. These individuals have disclosed that they have had no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.

Chirag Patel, PharmD, Director, Clinical Services, Institute for Continuing Healthcare Education, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of this activity.

Elizabeth Paczolt, MD, FACNP has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of this activity.

The educational content of this activity has been reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.

General Disclosure and Copyright
The opinions expressed at this symposium are those of the participating faculty and not those of the Institute for Continuing Healthcare Education, Incyte Corporation, or any manufacturers of products mentioned herein.

The information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional relative to diagnostic and treatment options of a specific patient’s medical condition. In no event will the Institute for Continuing Healthcare Education be responsible for any decision made or action taken based upon the information provided through this activity.

Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosage, and contraindications. This recommendation is particularly important with new or infrequently used products.

Provided as an educational service of

This activity is supported by an educational grant from

Copyright 2009-2010, Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this presentation may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from the Institute.